Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.57 |
| ▸ | ITGB7 | P26010 | 20/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674830 | 0.94 | ITGB1 (0.58) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL12341795 | 0.92 | ITGB1 (0.60) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2852357 | 0.90 | ITGB1 (0.64) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2852354 | 0.90 | ITGB1 (0.64) | ITGB1ITGA4ITGB7 | |
| SCHEMBL4200426 | 0.87 | ITGB1 (0.68) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2852295 | 0.87 | ITGB1 (0.61) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2846435 | 0.87 | ITGB1 (0.60) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2844237 | 0.87 | ITGB1 (0.64) | ITGB1ITGA4ITGB7 | |
| SCHEMBL1413115 | 0.87 | ITGB1 (0.64) | ITGB1ITGA4ITGB7 | |
| SCHEMBL8235084 | 0.86 | ITGB1 (0.62) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2231623-A1 | 5-PHENYL-LH-BENZ0 [E] [1, 4] DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS | Universita' Degli Studi di Firenze (IT) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2009081349-A1 | 5-PHENYL-LH-BENZ0 [E] [1, 4] DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2009-07-02 | — | — | WO | disclosed |
| US-20070027131-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins | ELAN PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7135477-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-7026328-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1635822-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040138243-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrins | WYETH | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027131-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins | VCAM1, ITGB4, ICAM1 | ITGB1 9/4885ITGA4 4/4885ITGB7 55/4885 |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | ITGB1 4/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ITGB1 305/4885ITGA4 298/4885ITGB7 485/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
| US-20040138243-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrins | VCAM1, ICAM1, ITGB4 | ITGB1 15/4885ITGA4 4/4885ITGB7 49/4885 |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.